Alterity Therapeutics Limited
ATH
Rangering i aksjer
#26014
Based in Melbourne, Australia, Alterity Therapeutics Limited, founded in 1997,... Based in Melbourne, Australia, Alterity Therapeutics Limited, founded in 1997, is dedicated to the discovery and advancement of treatments for neurological conditions such as Alzheimer's, Huntington's, and Parkinson's diseases, among others. The company's primary drug candidate, ATH434, has successfully navigated Phase I clinical trials for Parkinson's disease. Additionally, it is progressing PBT2, an investigational compound for Alzheimer's disease that has completed Phase 2a clinical trials. The firm, previously known as Prana Biotechnology Limited, adopted its current name, Alterity Therapeutics Limited, in April 2019.
Aksjekurs
$0.1904269
Markedsverdi
$41.61M
Endring (1 dag)
-3.57%
Endring (1 år)
-45.59%
Land
AU
Handel Alterity Therapeutics Limited (ATH)
Kategori
Healthcare
Utbytteavkastning for Alterity Therapeutics Limited (ATH)
Alterity Therapeutics Limited (aksjesymbol: ATH) sin utbytteavkastning (TTM) per 2026 er: 0
Gjennomsnittlig utbytteavkastning de siste 5 årene: 0.00%
Gjennomsnittlig utbytteavkastning de siste 5 årene: 0.00%
Utbytteavkastning for Alterity Therapeutics Limited (ATH) fra 2026 til 2026
Utbytteavkastning ved slutten av hvert år (TTM)
| År | Utbytteavkastning | Endre |
|---|---|---|
| Ikke nok data for de angitte datoene. | ||
Utbytteavkastning (TTM) for lignende selskaper eller konkurrenter
| Selskap | Utbytteavkastning | Land |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 2.17% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
